Thye Dirk 4

What Happened

• Dirk Thye, CEO, Chief Medical Officer and a director of Quince Therapeutics (QNCX), was granted a derivative award of 1,000,000 shares on January 23, 2026. The grant is reported as price $0.00 (no cash paid at grant) and is coded as an award/acquisition (A) on the Form 4. This is a compensation grant rather than an open‑market purchase or sale.

Key Details

• Transaction date and price: January 23, 2026; 1,000,000 shares at $0.00 (derivative award, code A).
• Shares owned after transaction: Not disclosed in this filing.
• Vesting: Per filing footnote, the award vests in equal monthly installments of 1/48th, with 1/48th vesting on the grant date and the remainder vesting monthly thereafter, fully vested on December 1, 2029.
• Filing timeliness: Reported and filed on January 23, 2026 (appears timely).

Context

• This is a derivative compensation award (Form 4 classifies it as an award/acquisition) with a monthly 48‑month vesting schedule; no cash was paid at grant. Such awards are common components of executive compensation and do not by themselves indicate the insider bought or sold company stock.